Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 4Urothelial Cancer 2Urinary Bladder Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasm Metastasis 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer 1Non Small Cell Lung Cancer NSCLC 1Nasopharyngeal Carcinoma 1Metastatic Urothelial Cancer 1Metastatic Adenocarcinoma of the Pancreas 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma 1Bile Duct Neoplasms 1

Interventions

pembrolizumab 25Cisplatin 9Paclitaxel 6Fluorouracil 5Carboplatin 4Saline Solution 3Capecitabine 3Bevacizumab 3Oxaliplatin 2Gemcitabine 2Docetaxel 2Cetuximab 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2lenvatinib 1Trastuzumab 1S 1 (combination) 1Irinotecan 1IFL protocol 1Glucose 1Doxorubicin 1Brentuximab Vedotin 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Parkinson Disease 4, Autosomal Dominant Lewy Body × Gemcitabine × Clear all
NCT04003636 2026-03-24

KEYNOTE-966

Merck Sharp & Dohme LLC

Phase 3 Completed
1,069 enrolled 19 charts 1 FDA
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT02819518 2024-11-27

KEYNOTE-355

Merck Sharp & Dohme LLC

Phase 3 Completed
882 enrolled 41 charts 1 FDA
Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡